TickerTalks
Browse all tickers →
TickerTalks›$SDGR
SDSDGR

Schrödinger, Inc.

$SDGR·$1.4B·Software - Application·Technology
$19.70-3.5%YTD-13.5%1Y-0.3%
Mentions · last 7 days
2026-08-20: 5 posts2026-08-21: 8 posts2026-08-22: 2 posts37+6%
Price updated 1d ago·X counts updated 7d ago
SDSDGR
$SDGRSchrödinger, Inc.
$19.70-3.48%37 posts+6%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $SDGR, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Comeback attemptAcceleratingAI verdict · as of 2026-08-20

The move is getting stronger, with heavier trading behind it.

AI-drug-discovery software company with a Lilly-Ajax milestone just landing — the platform economics are quietly turning.

Schrödinger sells a computational-chemistry software platform to pharma companies for drug design (subscriptions) plus co-owns internally-developed drug candidates that get partnered out. The story has been the twin engine: software subscriptions compound while the internal pipeline generates milestone payments as assets get out-licensed.

  • The Q2 print delivered on the surprise math: EPS of $0.08 beat the negative $0.41 consensus by 119% — driven by a specific one-time item plus stronger-than-modeled software revenue, but the direction of the surprise matters more than the absolute number.
  • The Lilly-Ajax milestone is the tape-changing news: Eli Lilly completed the acquisition of Ajax Therapeutics (Schrödinger co-founded), triggering the SDGR equity milestone — this validates the drug-discovery-partnership economics, and future Ajax-like exits are exactly what makes the platform's optionality real.
  • The valuation still leaves room even after the recent 12% jump: 4x trailing sales on a business with a growing software franchise plus internal drug candidates — bulls frame the potential multiple as 30x if the AI-drug-discovery cohort (ABCL/RXRX/RLAY) re-rates as a group, which is a real optionality piece.

Trajectory is accelerating with volume 1.8x the 30-day average as the Ajax exit filters through; the Nov 4 Q3 print needs continued software-revenue growth plus commentary on remaining pipeline out-licensing candidates — a soft software print or a delayed pipeline milestone breaks the setup after the recent tape action.

Agrees with X sentimentX's bullish AI-drug-discovery-cohort framing with ABCL/RXRX/RLAY and the 30x-multiple upside case is a stretch but directionally on-theme — Schrödinger's platform is genuinely differentiated. The added specific catalyst worth flagging: the Lilly-Ajax completed acquisition triggered a real cash milestone for SDGR that isn't yet fully in analyst models.

What to watch: Nov 4 Q3 earnings — continued software-revenue growth plus commentary on remaining pipeline out-licensing candidates sustains the setup; a soft software print or a delayed pipeline milestone breaks the setup after the recent tape action.

On the calendar: 2026-11-04 — Q3 2026 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment5 posts analyzed · as of 2026-07-09

Schrödinger contributors highlight the AI-driven biotech sector regime in a synchronized bullish acceleration phase alongside ABCL, RXRX, and RLAY. Bulls describe SDGR as trading at 4x with the bio-plus-AI thesis potentially supporting a 30x multiple, framing it as a powerful multi-theme setup with enterprise software and biotech/pharma both catching bids. Tone leans constructive on the AI-driven drug discovery thesis.

Read the AI verdict + X sentiment for $SDGR

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Provides physics-based computational drug discovery software to pharma companies and runs an internal drug pipeline.

Industry overviewAI analysisGenerated by AI from underlying data

Where Software - Application sits in its cycle right now — and what that implies for $SDGR.

Software - Application · Technology

No material change from last week — platforms where agents expand contract value (ServiceNow, Snowflake) are re-rated upward, while tools where agents substitute human users (Adobe Creative..

What this means for $SDGR

Neutral — Provides physics-based computational drug discovery software to pharma companies and runs an internal drug pipeline; limited read-through from software - application macro dynamics to this specific revenue mix.

Top industry ETF

$IGViShares Expanded Tech-Software Sector ETF
-4.2%YTD
+0.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-10.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-34.3%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-64.7%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-13.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
4.2Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-30.8%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
55.3%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.3Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 5, 2026$0.08$-0.41+119.3%
Q1 2026May 5, 2026$-0.81$-0.56-44.6%
Q4 2025Feb 25, 2026$0.44$-0.13+438.5%
Q3 2025Nov 5, 2025$-0.45$-0.75+40.0%
Next earningsWed, Nov 4·consensus EPS $-0.68

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$58.6M-1.6%50.4%-83.3%$-0.81$-17.3M
Q4 FY25$87.2M-1.2%65.7%-19.7%$0.44$-16.1M
Q3 FY25$54.3M+53.9%51.6%-84.6%$-0.45$-62.4M
Q2 FY25$54.8M+15.7%47.8%-96.6%$-0.59$-52.5M

Forward consensus

5-year forecast · up to 6 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$234.7M$225.9M – $244.8M-$2.00-$2.84 – -$1.106
FY27$265.2M$222.9M – $342.1M-$1.22-$2.57 – $0.526
FY28$323.2M$316.4M – $330.0M$0.22-$2.75 – $2.034
FY29$371.8M$336.4M – $448.7M-$0.01-$0.01 – -$0.013
FY30$406.5M$367.7M – $490.5M$0.40$0.35 – $0.513

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.72%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+16.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+31.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJul 16Rachit JainCFO875 sh$14KSellApr 17Ramy FaridCEO43.0K sh$525KSellApr 16Ramy FaridCEO43.0K sh$530KSellApr 16Rachit JainCFO844 sh$11KSellMar 6Jenny HermanCAO608 sh$8KSellMar 5Ramy FaridCEO3.7K sh$47KSellMar 5Rachit JainCFO1.6K sh$21KSellMar 5Karen AkinsanyaSee Remarks1.4K sh$18KSellMar 5Lorton Kenneth PatrickCOO1.2K sh$16KSellMar 5Jenny HermanCAO775 sh$10K
1–10 of 12
+ 12 other (9 awards · 2 exempts · 1 gift) in window

See when $SDGR insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDJun 298-K — Item 7.01: Press release / Reg FD
AI summary

Schrödinger, Inc. (SDGR) disclosed under Reg FD that Eli Lilly and Company has completed its acquisition of Ajax Therapeutics, Inc., a company co-founded by Schrödinger. As a co-founder and equity holder in Ajax, Schrödinger is entitled to receive acquisition proceeds from the Lilly closing. The specific dollar amount flowing to Schrödinger is not disclosed in the excerpt. This is a meaningful cash catalyst — milestone or equity proceeds from a Lilly acquisition could be material relative to Schrödinger's balance sheet and cash position.

8-KOfficer or director changeJun 238-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

________________________________________ Delaware 001-39206 95-4284541 reported departure or retirement of an officer: registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. At the 2026 Annual Meeting of Stockholders of Schr. ________________________________________ Delaware 001-39206 95-4284541 disclosed voting results from its annual or special meeting. registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. At the 2026 Annual Meeting of Stockholders of Schr...

8-KOfficer or director changeJun 88-K — Item 5.02: Officer or director change
AI summary

Schrödinger, Inc. (SDGR) formalized the separation of former Chief Commercial Officer Mannix Aklian on June 5, 2026, entering a transition, separation, and release agreement providing nine months of salary continuation, 12-month COBRA reimbursement, and additional benefits per his employment agreement and the company's Executive Severance Plan. The departure was previously disclosed; this filing confirms the financial terms. Routine executive separation with no new financial surprises.

8-KOfficer or director changeMay 208-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
AI summary

Schrodinger, Inc. (SDGR) filed an 8-K under Item 5.02 disclosing a change in its executive leadership or board composition. The filing reports both a departure and an appointment in President. Individuals named in the filing include Floor New, Its Charter. Leadership changes at the C-suite and board level are material events requiring 8-K disclosure within four business days, as they can affect company strategy, investor confidence, and operational continuity.

3New insider — initial holdingsMar 193
AI summary

Form filed by More than One Reporting Person Table I - Non-De filed a Form 3 (initial ownership statement) for SDGR on 2026-03-19, initiating required Section 16 reporting. Role: of Reporting Person. Beneficial ownership covers 2029 shares. Form 3 is a mandatory administrative filing upon first becoming an insider or 10%+ holder; it does not reflect a purchase or sale event.

8-KOfficer or director changeMar 128-K — Item 5.02: Officer or director change
+ 12 other (4 13Gs · 2 10-Qs · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharmazacks.com·13d agoSchrodinger Inc (SDGR) Stock Down 4.8% -- Now Undervalued? GF Score: 73/100gurufocus.com·15d agoSchrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)gurufocus.com·16d agoSchrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)businesswire.com·16d agoCritical Review: Schrodinger (NASDAQ:SDGR) versus Weave Communications (NYSE:WEAV)defenseworld.net·16d ago

More in Software - Application

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MSTR$ZETA$BULL$APP$SNOW$UBER$NOW$STRC
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport